Loading...
Market
How much will Natco Pharma's revenue increase due to the US patent settlement by end of 2024-25 fiscal year?
2
Resolution / Starting Odds
Less than 10% increase • 25%
10% to 20% increase • 25%
20% to 30% increase • 25%
More than 30% increase • 25%
Natco Pharma's official financial reports
Story
Natco Pharma Surges Nearly 4% Following US Patent Settlement on Generic Ozempic with Mylan Pharma
Oct 7, 2024, 03:19 AM
Natco Pharma has seen a significant boost in its stock price, surging nearly 4%, following the announcement of a settlement in the U.S. patent litigation concerning the generic version of Ozempic. The company, in partnership with Mylan Pharma, reached an agreement with Novo Nordisk, resolving the dispute over the diabetes medication. This settlement is expected to positively impact Natco's financial performance, building on the company's recent 47% increase in net profits for the 2023-24 fiscal year, driven by the success of its patent challenges in the U.S. market.
View original story
Similar markets
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Revenue increases • 25%
Revenue decreases by less than 10% • 25%
Revenue decreases by 10-25% • 25%
Revenue decreases by more than 25% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Below 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
Above 15% • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%